Targeted therapy in combination with an agent that enhances terminal differentiation of cancer cells

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Currently, for the treatment of oncological diseases, in addition to standard treatment methods, an approach is being developed in which terminal differentiation of cancer cells is induced with the help of pharmacological drugs, leading to an increase in the therapeutic effect under the influence of traditional treatment methods. A number of examples of the use of dimethyl sulfoxide (DMSO) as a safe adjuvant that stimulates the differentiation of various types of the cancer cells, have been described in the literature. In this paper, we propose a method for elimination of human ovarian cancer cell adenocarcinomas SKOV3.ip1, including targeted therapy based on the HER2-specific toxin DARP-LoPE and DMSO as an enhancing agent for terminal differentiation of cancer cells.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Е. Shramova

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russian Academy of science; P.N. Lebedev Physical Institute of the Russian Academy of Sciences

Хат алмасуға жауапты Автор.
Email: shramova.e.i@gmail.com
Ресей, Moscow; Moscow

G. Proshkina

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russian Academy of science

Email: shramova.e.i@gmail.com
Ресей, Moscow

I. Zavestovskaya

P.N. Lebedev Physical Institute of the Russian Academy of Sciences; National Research Center “Kurchatov Institute”

Email: shramova.e.i@gmail.com
Ресей, Moscow; Moscow

S. Deyev

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russian Academy of science; P.N. Lebedev Physical Institute of the Russian Academy of Sciences; National Research Center “Kurchatov Institute”; Sechenov First Moscow State Medical University (Sechenov University)

Email: shramova.e.i@gmail.com

Academician of the RAS

Ресей, Moscow; Moscow; Moscow; Moscow

Әдебиет тізімі

  1. Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ “НМИЦ радиологии” Минздрава России; 2024.
  2. de Thé H. Differentiation therapy revisited // Nat Rev Cancer. 2018. Vol. 18. P. 117–127.
  3. Hoang B.X., Han B.O., Fang W.H., et al. The rationality of implementation of dimethyl sulfoxide as differentiation-inducing agent in cancer therapy // Cancer Diagn Progn. 2023. Vol. 3, N 1. P. 1-8.
  4. Прошкина Г.М., Киселева Д.В., Шилова О.Н., и др. Бифункциональный токсин DARP-LOPE на основе HER2-специфичного инновационного модуля неиммуноглобулиновой природы как перспективный агент для тераностики // Молекулярная биология. 2017. Т. 51, №6. С. 997–1007.
  5. Sokolova EA, Shilova ON, Kiseleva DV, et al. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model // Int J Mol Sci. 2019. Vol. 20, N 10. P. 2399.
  6. Yu D., Wolf J.K., Scanlon M., et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A // Cancer Res. 1993. Vol. 53, N 4. P. 891–898.
  7. Шрамова Е.И., Фролова А.Ю., Филимонова В.П., и др. Система для самоактивируемой адресной фотодинамической терапии на основе мультимодального белка DARP-NanoLuc-SOPP3 // Acta Naturae. 2023. Т.15, №4. C. 100–110.
  8. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays // J Immunol Methods. 1983. Vol. 65. P. 55–63.
  9. Galogre M., Rodin D., Pyatnitskiy M., et al. A review of HER2 overexpression and somatic mutations in cancers // Critical Reviews in Oncology/Hematology. 2023. Vol. 186, P. 103997.
  10. Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy // Annu Rev Pharmacol Toxicol. 2015. Vol. 55. P. 489–511.
  11. Iqbal N., Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications // Mol Biol Int. 2014. Vol. 2014. P. 852748.
  12. Согомонян А.С., Шипунова В.О., Соловьев В.Д., и др. Метод получения трехмерных клеточных сфероидов: универсальный инструмент для изучения цитотоксических свойств противоопухолевых соединений in vitro // Acta Naturae. 2022. Т. 14, №1. C. 92–100.
  13. Verma N., Tiku A.B. Significance and nature of bystander responses induced by various agents // Mutat Res Rev Mutat Res. 2017. Vol. 773, P. 104–121
  14. Казанцев И.В., Геворгян А.Г., Юхта Т.В., и др. Иммунотерапия специфическими антителами к GD2 у пациентов с нейробластомой группы высокого риска, а также пациентов с первично-резистентными формами и рецидивами нейробластомы: опыт НИИ ДОГиТ им. Р.М. Горбачевой ПСПбГМУ им. акад. И.П. Павлова // Российский журнал детской гематологии и онкологии. 2021. Т.8, №3. С. 14–29.
  15. Moussalli M.J., Wu Y., Zuo X., et al. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion15-lox-1 and terminal cell differentiation loss in cancer // Cancer Pre Res. 2011. Vol. 4, N12. P. 1961–1972.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Combined effect of the differentiating agent DMSO and the targeted HER2-specific toxin DARP-LoPE on 2D culture of SKOV3.ip1 cells (A) and 3D spheroids of mixed type consisting of SKOV3.ip1 cells, endothelial-derived EA.hy926 cells and BJ-5TA stromal fibroblasts (B).

Жүктеу (87KB)
Метадеректер

© Russian Academy of Sciences, 2025